{"entity":{"id":"nct07502300","kind":"trial","name":"A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Pa","aka":[],"tldr":"A phase 3 trial of Izalontamab brengitecan, Tislelizumab, Carboplatin in small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.","summary":"A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07) is a phase 3 interventional study registered as NCT07502300 by Sichuan Baili Pharmaceutical Co., Ltd., with 562 participants planned, started 2026-06-15 and due to reach its primary completion in 2029-12. Interventions recorded: BL-B01D1, Tislelizumab, Carboplatin, Etoposide. Conditions listed: Extensive-stage Small-cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07502300","url":"https://clinicaltrials.gov/study/NCT07502300"}],"tags":["ctgov-ingest"],"related":[],"cancers":["sclc","extensive-stage-sclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["izalontamab-brengitecan","tislelizumab","carboplatin","etoposide"],"companies":["systimmune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07502300","phase":"3","setting":"A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 for Injection Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","started":"2026-06-15","startedType":"actual","enrolled":562,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07502300/","neighbours":{"cancer":[{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/"},{"id":"izalontamab-brengitecan","kind":"drug","name":"Izalontamab brengitecan","route":"/drugs/izalontamab-brengitecan/"},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"company":[{"id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","route":"/companies/systimmune/"}]}}